Andrew A. Fuqua

Andrew A. Fuqua

Auto-generated profile, based on publicly available information

Andrew A. Fuqua

Department of Orthopaedic Surgery, Emory University School of Medicine, 21 Ortho Lane, Atlanta, GA 30329

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2025 in The Knee
Verified
Journal Article
Open access
AFAndrew A. Fuqua
Andrew A. Fuqua
JWJacob A. Worden
Jacob A. Worden
AAAyomide M. Ayeni
Ayomide M. Ayeni
KBKyle E. Bundschuh
Kyle E. Bundschuh
APAjay Premkumar
Ajay Premkumar
JWJacob M. Wilson
Jacob M. Wilson
Recent evidence has emerged supporting the use of extended oral antibiotic (EOA) prophylaxis after primary total knee replacement (TKA) to reduce periprosthetic joint infection (PJI) in high-risk patients. However, much of the evidence stems from single-institution series with limited sample sizes. This study aimed to explore the impact of EOA on complications and infection-free survivorship in a large cohort of patients after primary TKA. A large national database was used to identify patients undergoing primary TKA from 2015 to 2022. Patients receiving 7-14 days of EOA were identified. Propensity-score matching, based on patient comorbidities, was used to match patients who received EOA and to control patients who did not. Three cohorts were created: any-risk, high-risk, and standard-risk. Complications at 90-days were assessed with univariate analysis and survivorship free of PJI to 2 years was analyzed with the Kaplan-Meier method and cox regression. We identified 5,701 patients who received EOA: 3,628 (64%) with high-risk comorbidities and 2,073 (36%) standard risk. There were no significant reduction in hazard of PJI at 90-days (any-risk: HR: 1.65, 95% CI: 0.90-3.04, P = 0.11; high-risk: HR: 1.37, 95% CI: 0.69-2.70, P = 0.4; standard-risk: HR: 1.51, 95% CI: 0.53-4.26, P = 0.4), 1 year (P > 0.07), or 2 years (any-risk: HR: 1.42, 95% CI: 0.98-2.05, P = 0.065; high-risk: HR: 1.14, 95% CI: 0.76-1.73, P = 0.5; standard-risk: HR: 1.51, 95% CI: 0.76-2.98, P = 0.2) with EOA administration. EOA prophylaxis was not associated with improved PJI-free survivorship at any measured time point following primary TKA in either high-risk or standard-risk risk patients. Given the observed widespread use of EOA, our study highlights the need for further investigation to delineate what specific populations may benefit from EOA prophylaxis.

13 February 2024 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
AFAndrew Fuqua
Andrew Fuqua
KHKevin Y Heo
Kevin Y Heo
JWJacob A. Worden
Jacob A. Worden
RGRahul K. Goel
Rahul K. Goel
GGGeorge N. Guild
George N. Guild
APAjay Premkumar
Ajay Premkumar

29 May 2024 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
AFAndrew A. Fuqua
Andrew A. Fuqua
JWJacob A. Worden
Jacob A. Worden
JBJanice M. Bonsu
Janice M. Bonsu
BRBailey J. Ross
Bailey J. Ross
APAjay Premkumar
Ajay Premkumar

13 June 2025 in Arthroplasty Today
Verified
Journal Article
Open access
AFAndrew A. Fuqua
Andrew A. Fuqua
JWJacob A. Worden
Jacob A. Worden
AAAyomide M. Ayeni
Ayomide M. Ayeni
KBKyle E. Bundschuh
Kyle E. Bundschuh
JWJacob M. Wilson
Jacob M. Wilson
APAjay Premkumar
Ajay Premkumar
Several studies have presented findings in favor of using extended oral antibiotic (EOA) prophylaxis to reduce periprosthetic joint infection (PJI) after primary total hip arthroplasty (THA) in patients at high risk for infection. To date, there is a paucity of evidence examining this topic from large retrospective databases. This study explored 90-day complication rates and 2-year PJI-free survivorship in a large cohort of patients receiving EOA prophylaxis after primary THA. A large national database was used to identify patients undergoing primary THA from 2009 to 2022. Patients receiving 7-14 days of EOA were identified and propensity score–matched based on comorbidities to controls not receiving EOA and subsequently stratified into any-risk, high-risk, and standard-risk cohorts based on infection-related risk factors. Complication rates at 90 days were examined, and 2-year PJI-free survivorship was assessed employing Kaplan-Meier curves and Cox regression analysis further adjusting for comorbidity status. A total of 4153 patients receiving EOA prophylaxis after THA were identified. Of those patients, 2154 (52%) were considered high risk for PJI, while 1999 (48%) were considered standard risk. Significant reduction in hazards of PJI with administration of EOA was not seen at 90 days (any-risk: hazard risk [HR]: 0.75, 95% confidence interval [CI]: 0.42-1.35, P = .3; high-risk: HR: 0.85, 95% CI: 0.39-1.85, P = .7; standard-risk: HR: 1.29, 95% CI: 0.44-3.77, P = .6), 1 year (any-risk: HR: 0.99, 95% CI: 0.68-1.44, P > .9; high-risk: HR: 1.24, 95% CI: 0.77-1.99, P = .4; standard-risk: HR: 1.56, 95% CI: 0.73-3.33, P = .3), or 2 years (any-risk: HR: 1.02, 95% CI: 0.73-1.42, P > .9; high-risk: 1.25, 95% CI: 0.82-1.91, P = .3; standard-risk: HR: 1.10, 95% CI: 0.61-2.00, P = .8). No significant increase in PJI-free survivorship at 90 days, 1 year, or 2 years was seen with EOA prophylaxis following primary THA. Reported PJI rates were low across all cohorts, irrespective of baseline risk. Further evidence is needed to adjudicate the efficacy of EOA prophylaxis after THA in addition to possible risks and appropriate indications for use.

19 September 2022 in Foot & Ankle Specialist
Verified
Journal Article
Closed access
AWAlex R. Webb
Alex R. Webb
WMWesley J. Manz
Wesley J. Manz
AFAndrew Fuqua
Andrew Fuqua
MCMichelle M. Coleman
Michelle M. Coleman
JBJason T. Bariteau
Jason T. Bariteau
RKRishin J. Kadakia
Rishin J. Kadakia
Background: While first metatarsophalangeal joint (MTPJ) arthrodesis is a common and effective procedure, there is a paucity of studies examining obesity’s effect on outcomes of 1st MTPJ arthrodesis. This study’s purpose was to evaluate patient-reported outcomes following 1st MTPJ arthrodesis in obese versus non-obese patients. Methods: A retrospective cohort study of 94 patients undergoing first MTPJ fusion over the age of 18 with a diagnosis of hallux valgus or hallux rigidus was performed. Surgical and postoperative outcomes were examined preoperatively and at 6 and 12 months follow-up via Visual Analog Pain scale (VAS), and Short Form 36 (SF-36) surveys, and data were stratified into 2 patient groups: BMI < 30 (n = 62, mean age 63.9 ± 9.1 and ≥ 30 (n = 32, mean age 61.9 ± 8.4). Results: Average overall VAS and SF-36 physical component scores improved significantly at 6 months ( P < .001, .006) and 1 year postoperative visits ( P < .001, .007) with no differences in survey scores, outcomes, or complications between weight groups. Conclusion: Our study showed first MTPJ fusion improves short-term pain and physical quality-of-life in arthritic obese and non-obese patients without differences in nonunion, complications, or patient-reported measures. Level of Evidence: Level III, Prognostic, Case-Control Study

11 July 2024 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
AFAndrew A. Fuqua
Andrew A. Fuqua
JWJacob A. Worden
Jacob A. Worden
BRBailey J. Ross
Bailey J. Ross
JBJanice M. Bonsu
Janice M. Bonsu
APAjay Premkumar
Ajay Premkumar